Validation study of the UICC TNM classification of malignant tumors, seventh edition, in breast cancer

Uehiro, Natsue; Horii, Rie; Iwase, Takuji; Tanabe, Masahiko; Sakai, Takehiko; Morizono, Hidetomo; Kimura, Kiyomi; Iijima, Kotaro; Miyagi, Yohei; Nishimura, Seiichiro; Makita, Masujiro; Ito, Yoshiaki; Akiyama, Futoshi

doi:10.1007/s12282-013-0453-7

Cited by 12 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7,8 However, tumor diameter, which has been used to express tumor size, does not always reflect actual tumor size in gastrointestinal tumors, especially in gastric cancer due to the inconsistent morphology and pattern of invasion of this carcinoma. Most of these studies have failed to demonstrate the validity of tumor diameter as an independent prognostic factor even if tumor diameter is considered as an independent prognostic factor.…”

Section: Discussionmentioning

confidence: 99%

Tumor volume as a prognostic factor was superior to the seventh edition of the pT classification in resectable gastric cancer

Jiang

Deng

Ding

et al. 2015

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Tumor volume as a prognostic factor was superior to the seventh edition of the pT classification in resectable gastric cancer

Jiang

Deng

Ding

et al. 2015

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

“…Pathohistological, grading and staging criteria for breast cancer were determined by using criteria from American Join Committee (AJC) and TNM classification according to UICC (International Union for Cancer Control) [ 8 ] [ 9 ]. According to the new classification system for breast cancer subtypes presented in St. Gallen, which we use, breast cancer is divided in Luminal A, Luminal B with HER2 negative, Luminal B with HER2 positive, HER2 enriched and basal-like (triple negative) [ 7 ].…”

Section: Methodsmentioning

confidence: 99%

Presentation of the Molecular Subtypes of Breast Cancer Detected By Immunohistochemistry in Surgically Treated Patients

Кондов¹,

Milenkovikj²,

Кондов³

et al. 2018

Open Access Maced J Med Sci

View full text Add to dashboard Cite

INTRODUCTION:The detection of estrogen, progesterone and HER-2 neu receptors on the surface of the tumour cell is a significant prognostic factor, alone or in combination. The presence or absence of receptors on the surface of the tumour cell is associated with the conditional gene expression in the tumour cell itself. Based on these genetically determined expressions of the tumour cell, five molecular subtypes of breast cancer have been classified on the St. Gallen International Expert Consensus in 2011 that can be immunohistochemically detected, with each subtype manifesting certain prognosis and aggression.AIM:Analyzing the presentation of molecular subtypes of breast cancer that are immunohistochemically detected in surgically treated patients at the Clinic for Thoracic and Vascular Surgery.MATERIAL AND METHODS:We used the international classification on molecular subtypes of breast cancer which divides them into: Luminal A (ER+ and/or PR+, HER-2 negative, Ki-67 < 14%), Luminal B with HER-2 negative (ER+ and/or PR+, HER-2 negative, Ki-67 ≥ 14%), Luminal B with HER-2 positive (ER+ and/or PR+, HER-2+, any Ki-67), HER-2 enriched (ER-, PR-, HER-2+), and basal-like (triple negative) (ER-, PR-, HER-2 negative, CK5/6+ and/or EGFR+). A total of 290 patients, surgically treated for breast cancer, were analysed during 2014.RESULTS:In our analysis, we found that Luminal A was present in 77 (26.55%) patients, Luminal B HER-2 negative was present in 91 (31.38%) patients, Luminal B HER-2 positive was present in 70 (24.14%) patients, HER-2 enriched was present in 25 (8.62%) patients and basal-like (or triple negative) was present in 27 (9.31%) patients.CONCLUSION:Detecting the subtype of breast cancer is important for evaluating the prognosis of the disease, but also for determining and providing an adequate therapy. Therefore, determining the subtype of breast cancer is necessary for the routine histopathological assay.

show abstract

“…The average age of the patients was 52 years. According to the 2017 AJCC staging standard and the 2014 UICC standard, there were 52 cases in stages I‐II, 59 cases in phase III‐IV, and 50 cases with lymph node metastasis. With regard to the impact of ZNF326 on the prognosis of patients with breast cancer, we used the online database KM‐plotter (http://kmplotter.org, 2010 database) for online analysis.…”

Section: Methodsmentioning

confidence: 99%

ZNF326 promotes a malignant phenotype of breast cancer by interacting with DBC1

Wang

Han

et al. 2018

Molecular Carcinogenesis

View full text Add to dashboard Cite

The biological role and underlying mechanism of action of zinc-finger protein 326 (ZNF326) in malignant tumors, including breast cancer, are still not clear. In this study, we detected high expression of ZNF326 in breast cancer specimens (60/111, 54.1%) and breast cancer cell lines (7/7); the expression level of ZNF326 was inversely associated with advanced pTNM stage (P = 0.002), positive lymph node metastasis (P = 0.004), poor prognosis in patients with breast cancer (P = 0.0097), and ER/PR/Her2 status (P = 0.013). Meanwhile, the ectopic expression of ZNF326 significantly upregulated MMP7, EMT-related proteins (Snail and Slug), and cell cycle-related proteins (cyclinA2 and cyclinB1); downregulated E-cadherin expression; and promoted the proliferation and invasiveness of breast cancer cells both in vivo and in vitro. Mechanistically, co-immunoprecipitation and immunofluorescence assays both demonstrated that ZNF326 interacted with deleted in breast cancer-1 (DBC1) in breast cancer cells. Additionally, DBC1 knockdown eliminated the up-regulation of MMP7, EMT-related proteins, and cell cycle-related proteins as well as the enhanced proliferation and invasiveness induced by ZNF326. Therefore, we concluded that ZNF326 is highly expressed in breast cancer, is associated with poor prognosis, and plays a vital role in promoting the malignant phenotype of breast cancer cells by interacting with DBC1.

show abstract

Validation study of the UICC TNM classification of malignant tumors, seventh edition, in breast cancer

Abstract: The latest revision of the TNM classification is appropriate for breast cancer from the perspective of prognosis.

Cited by 12 publications

References 14 publications

Tumor volume as a prognostic factor was superior to the seventh edition of the pT classification in resectable gastric cancer

Tumor volume as a prognostic factor was superior to the seventh edition of the pT classification in resectable gastric cancer

Presentation of the Molecular Subtypes of Breast Cancer Detected By Immunohistochemistry in Surgically Treated Patients

ZNF326 promotes a malignant phenotype of breast cancer by interacting with DBC1

Contact Info

Product

Resources

About